FDA Granted Pediatric Disease Designation for OXi-4503
16 sept. 2020 09h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that the US...
Mateon’s Global Study for Artemisinin Intervention Against COVID-19 Cleared for Patient Enrollment in India
14 sept. 2020 07h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its...
Mateon Therapeutics Closes $2.0 Million Financing
27 juil. 2020 07h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its...
Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19
20 juil. 2020 07h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study...
Mateon Therapeutics to fund observational studies of Artemisinin in developing countries
13 juil. 2020 07h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for...
Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
24 juin 2020 07h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative...
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
23 juin 2020 07h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
Mateon and GMP Completed Research and Service Agreement
22 juin 2020 08h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have...
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO
10 juin 2020 08h00 HE
|
Mateon Therapeutics
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of...
Mateon Announces an Expansion to its Pharmaceutical Manufacturing AI Camera Grid by Including Contact Tracing to Ensure Worker Safety
08 juin 2020 05h00 HE
|
Mateon Therapeutics
TracePoint vision grid will identify workers who came in contact with a sick coworker and alert operational staff.Mateon’s patented AI camera grid system is similar to Amazon’s technology but at a...